Guideline-Directed Medical Therapy in Heart Failure: The Need for Speed

News & Events

Guideline-directed medical therapyAnnouncing a new article publication for Cardiovascular Innovations and Applications journal. Heart failure (HF) represents one of the most pressing health challenges globally, affecting more than 64 million people worldwide. Despite therapeutic progress, HF remains a leading cause of hospitalization and mortality, particularly in patients with reduced ejection fraction (HFrEF), with annual costs, including hospitalizations, pharmacotherapy, and productivity losses, measured in the hundreds of billions of dollars. Readmissions remain common: roughly one in four patients is rehospitalized within 30 days in many healthcare systems, and one in two within 6 months, reflecting not only the complexity of patients with HF but also the challenges of post-discharge care.Despite decades of advances, 5-year mortality in HF approximates that of many cancers, thereby underscoring the urgency for better care delivery.

Read full open access article at https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2025.0042

# # # # # #

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Alvina Karam and Juan M. Aranda. Guideline-Directed Medical Therapy in Heart Failure: The Need for Speed. CVIA. 2026. Vol. 11(1). DOI: 10.15212/CVIA.2025.0042

Loading